In vivo Efficacy of Relebactam (MK-7655) in Combination with Imipenem/Cilastatin in Murine Infection Models.

In vivo Efficacy of Relebactam (MK-7655) in Combination with Imipenem/Cilastatin in Murine Infection Models. Antimicrob Agents Chemother. 2018 Jun 04;: Authors: Powles MA, Galgoci A, Misura A, Colwell L, Dingley KH, Tang W, Wu J, Blizzard T, Motyl M, Young K Abstract The World Health Organization has identified antimicrobial resistance as a global public health threat as the prevalence and spread of antibiotic resistance among bacterial pathogens worldwide are staggering. Carbapenems, such as imipenem and meropenem have been used to treat multidrug-resistant bacteria; however, since the development of resistance to carbapenems, β-lactam antibiotics in combination with β-lactamase inhibitors (BLI) has been one of the most successful strategies to enhance the activity of β-lactam antibiotics. Relebactam (REL) is a new BLI which has been found to inhibit Class A and Class C β-lactamases in vitro. REL has been reported to restore imipenem's activity against both imipenem-resistant Pseudomonas aeruginosa and Klebsiella pneumoniae. Reported here are the in vivo efficacy studies of the imipenem-cilastatin (IMI)/REL combination in mouse models of disseminated and pulmonary infection caused by imipenem-resistant clinical isolates of P. aeruginosa and K. pneumoniae The combination was also evaluated in a P. aeruginosa delayed pulmonary model of infection. IMI/REL was found to be effective in the disseminated model of infection with log red...
Source: Antimicrobial Agents and Chemotherapy - Category: Microbiology Authors: Tags: Antimicrob Agents Chemother Source Type: research